In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $27.23, denoting a +1.57% change from the preceding trading day.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

The founding coalition members are: Albertsons Companies, Inc., Circle Medical, Foodsmart, hims & hers, Lifepoint Health, Nixon Law Group, Nourish, and Teladoc Health. With RFK, Jr. as head of Health ...

A new analysis by Freedom24 reveals that investors across the Baltic States — Estonia, Latvia, and Lithuania — are actively engaging with global trends in AI, technology, and cryptocurrencies, while ...

Truist analyst Jailendra Singh lowered the firm’s price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter ...